Cefuroxime: profile and news






Rethinking UTI Prophylaxis  Mar 1, 2006
...and history of UTI or those receiving prophylaxis had lower sensitivity to amoxicillin, cefazolin, cefepime, cefotaxime, ceftazadime, cefuroxime, or TMP-sulfa ... - AAP Grand Rounds (subscription)

Orbus Signs Licensing, Supply and Contract Manufacturing ...  Feb 9, 2006
On November 7, 2005 Orbus announced that it had received notification of regulatory approval for cefuroxime axetil from the Danish Medicines Authority. ... - CCNMatthews (press release),

Orbus Signs Licensing, Supply and Contract Manufacturing ...  09 Feb 2006
On November 7, 2005 Orbus announced that it had received notification of regulatory approval for cefuroxime axetil from the Danish Medicines Authority. ... - CCNMatthews (press release),

GCGMH denies exclusive contract with drug firm  Jan 28, 2006
Under the Cathay contract, exclusive medicines sold at the hospital include Cefuroxime vial 750 mg costing P220; Benzathine Penicillin (Penadur) at P135 ... - Bohol Chronicle,

Head-To-Head Study Shows More Elderly Patients With Community ...  Jan 24, 2006
...following antibiotic classes: penicillin (MIC greater than or equal to 2 mcg/mL), second generation cephalosporins (eg, cefuroxime), macrolides, tetracyclines ... - PR Newswire (press release),

New safety scheme in Tallaght Hospital highlights common drug ...  Jan 20, 2006
Of 102 prescribing errors analysed, 22 involved insulin; 14 fentanyl patches; 13 morphine; 13 co-amoxiclav; 12 cefuroxime; 10 diclofenac; 10 enoxaparin; and ... - Irish Medical News,

Hospital forges exclusive contract with drug company  Jan 14, 2006
These include Cefuroxime vial 750 mg costing P220; Benzathine Penicillin (Penadur) at P135; Benzylpenicillin Sod 1 mil at P25; and Benzylpenicillin Sod 5 mil ... - Bohol Chronicle,

FDA Approves New Indication for Avelox (moxifloxacin HCl) for ...  Nov 30, 2005
...following antibiotic classes: penicillin (MIC greater than or equal to 2 mcg/mL), second generation cephalosporins, eg, cefuroxime, macrolides, tetracyclines ... - DG News

Oscient Pharmaceuticals Submits sNDA to FDA for Five-Day Treatment ...  Nov 21, 2005
...safety data from five Phase III trials involving more than 1,800 patients receiving FACTIVE and 500 patients receiving a comparator (trovafloxacin or cefuroxime ... - PharmaLive.com (press release),

Orbus Signs Cefuroxime Axetil Licensing and Supply Agreement  Sep 27, 2005
...six months. Retail annual sales of cefuroxime axetil in Spain, Italy and Belgium are approximately 60 million Euros. Orbus will ... - CCNMatthews (press release),

US party over for Indian pharma  Oct 4, 2005
Two of the biggest successes in recent times in the US have been the Cefuroxime story of Ranbaxy and the Fluoxetine story of Dr Reddy's. ... - Rediff,

Clinical Data on FACTIVE(R) Tablets for ABS and AECB Presented at ...  Oct 7, 2005
The retrospective analysis determined that FACTIVE, compared to the other drugs studied (cefuroxime and trovafloxacin), was more effective in treating ABS in ... - Genetic Engineering News,

Ranbaxy guns for Pfizer's $12-b cholesterol drug — Generic cos ...  Sep 12, 2005
Among other significant litigations, Ranbaxy had also fought a long legal battle for the US market to launch the generic cefuroxime axetil sold under the ... - Hindu Business Line,

Finding best generic drug  Sep 19, 2005
For example, the Walgreens at Michigan and Chicago and the online Drugstore.com both sell 250-milligram tablets of generic cefuroxime, a powerful antibiotic ... - Chicago Sun-Times,

Microbiological activity of telithromycin against Streptococcus ...  Sep 21, 2005
Amoxicillin- clavulanate 97.6 0.12 96.3 2 94.4 2 ----- Cefuroxime 89.5 0.5 85.0 4 79.2 8 ... - Canada NewsWire (press release),

Nitrous Oxide Does Not Increase Postop Infection Risk  Sep 22, 2005
The patients were randomly assigned to undergo standard anesthesia induction, at which time all patients received intravenous cefuroxime and metronidazole. ... - MedPage Today,

FDA Safety Labeling Changes: Cefuroxime, Zocor, Clozaril  Aug 31, 2005
May and June revisions to safety labeling to advise that oral vancomycin is considered the treatment of choice for severe cefuroxime-related pseudomembranous ... - Medscape (subscription)

Lupin gets USFDA nod  Aug 18, 2005
Earlier it had received approvals for Ceftriaxone for injection, Cefotaxime for injection, Cefuroxime Axctil tablets and Cefixime tablets and oral suspension. - Sify,

Acute Bacterial Sinusitis - Levaquin® (levofloxacin) FDA Approved ...  Aug 15, 2005
...more of the following antibiotics: penicillin (MIC greater than or equal to 2 mcg/mL), 2nd generation cephalosporins, eg cefuroxime, macrolides, tetracyclines ... - Medical News Today (press release),

Wockhardt gets USFDA nod for cefuroxime axetil  Aug 2, 2005
Wockhardt has received approval from the United States Food & Drug Administration (USFDA) for marketing cefuroxime axetil in the US market. ... - Business Standard

Orbus Signs Cefuroxime Axetil Licensing Agreement  Jul 25, 2005
Cefuroxime axetil is an antibiotic used to treat certain infections such as bronchitis, infections of the ears, throat, sinuses, urinary tract and skin. ... - CCNMatthews (press release)

Wockhardt gets USFDA nod for antibiotic  Aug 5, 2005
Pharmaceutical and biotechnology major Wockhardt Ltd has received approval from the United States Food & Drug Administration for marketing cefuroxime axetil in ... - Business Standard

Wockhardt jumps up on USFDA nod  Aug 2, 2005
...up at the BSE after the Mumbai-based domestic drug firm received approval from the US Food & Drug Administration (USFDA) for marketing cefuroxime axetil in the ... - Business Standard

L&T plant in China  Aug 2, 2005
Mumbai, Aug. 2: Wockhardt Limited has received approval from the United States Food & Drug Administration to market cefuroxime axetil in the US. - Calcutta Telegraph <**results**>

Steroid Nasal Sprays Seem to Speed Sinusitis Recovery  Jun 30, 2005
All participants were given two puffs of the decongestant xylometazoline hydrochloride twice daily for three days and the antibiotic cefuroxime axetil twice ... - eMaxHealth.com

Schering-Plough Announces FDA Approval of AVELOX(R) (moxifloxacin ...  Jun 30, 2005
...following antibiotic classes: penicillin (MIC equal to or greater than 2 mcg/mL), second generation cephalosporins, eg cefuroxime, macrolides, tetracyclines ... - Yahoo News (press release)

Tick-Borne Disease  Jun 26, 2005
Cefuroxime (Ceft\in; 500 mg orally, twice per day) or erythromycin (250 mg orally, four times per day) can be prescribed for persons who are allergic to ... - RedNova.com,

Tick-Borne Disease  Jun 26, 2005
Cefuroxime (Ceft\in; 500 mg orally, twice per day) or erythromycin (250 mg orally, four times per day) can be prescribed for persons who are allergic to ... - RedNova.com,

Ketek(R) offers the first five-day antibiotic treatment for acute ...  Apr 25, 2005
85.2 per cent were cured with a once-a-day, five-day Ketek treatment, versus 82.0 per cent for those treated with the antibiotic cefuroxime axetil three times ... - Canada NewsWire

New Data Illustrate Geographic Variance in Rates of Drug Resistant ...  Apr 5, 2005
...strains resistant to two or more of the following antibiotics: penicillin, second generation cephalosporins (eg cefuroxime), macrolides, tetracyclines and ... - Business Wire,

GSK Re-Packages Product  Feb 18, 2005
According to the company's marketing and business development director, Mr. Greig Baines, the antibiotic, a brand of Cefuroxime axetil now comes in a smaller ... - AllAfrica.com,


Other information


Indication
For the treatment of the following infections (respiratory, skin, soft tissue, urinary tract infections, ear, nose, throat infectsion) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A ß-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph. Also used to treat acute bacterial bronchitis in patients with COPD

Pharmacology
Cefuroxime, a second-generation cephalosporin, is used to treat severe upper and lower respiratory tract infections, skin infections, otitis media, and surgical prophylaxis.

Mechanism Of Action
Cefuroxime, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefuroxime interferes with an autolysin inhibitor.

Drug Category
Anti-bacterial Agents; Cephalosporins; ATC:J01DC02

Brand Names/Synonyms
Ancef; Biofuroksym; Ceclor; Ceclor Cd; Cedax; Cefditoren; Cefizox; Cefotan; Ceftin; Ceftizoxime Sodium; Cefurax; Cefuril; Cefuroxim; Cefuroxime; Cefuroxime Axetil; Cefuroxime Free Acid; Cefuroxime Sodium; Cefuroxime Sodium Salt; Cefuroxime [Usan:Ban:Inn]; Cefuroxime and Dextrose in Duplex Container; Cefuroximo [Inn-Spanish]; Cefuroximum [Inn-Latin]; Cefzil; Cephuroxime; Ceptaz; Duricef; Elobact; Fortaz; Keflex; Keftab; Kefurox; Kefurox in Plastic Container; Kerurox; Mandol; Maxipime; Mefoxin; Monocid; Omnicef; Oraxim; Rocephin; Sharox; Tazicef; Vantin; Velosef; Zinacef; Zinacef Danmark; Zinacef in Plastic Container; Zinat; Zinnat

Dosage Forms
POWDER; POWDER FOR SOLUTION; TABLET

Absorption
Well absorbed from the GI tract (bioavailability is 37-52%)

Interactions
-->Interactions for Cefuroxime:

Drug/Laboratory Test Interactions: A false-positive reaction for glucose in the urine may occur with copper reduction tests (Benedictís or Fehlingís solution or with ClinitestÒ tablets) but not with enzyme-based tests for glycosuria. As a false-negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase method be used to determine blood plasma glucose levels in patients receiving cefuroxime.

Cefuroxime does not interfere with the assay of serum and urine creatinine by the alkaline picrate method.



Chemical IUPAC Name
4-(carbamoyloxymethyl)-8-[2-(2-furyl)-2-methoxyimino-acetyl]amino-7-oxo-2-thia-6-azabicyclo[4.2.0]oct-4-ene-5-carboxylic acid

Chemical Formula
C16H16N4O8S

Half Life
~80 minutes

Drug Type
Approved Drug

# Accession No
APRD00285

CAS Registry Number
55268-75-2

Home | About | Cancers | Treatment | Medications
Copyright onconews.org 2005.
All Rights Reserved.
Google
 
Web onconews.org